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Background: Lymphopenia is the most important criterion of mortality and discharging feature for patients infected with coronavirus
disease 2019 (COVID-19). This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment
on the clinical course of COVID-19.
Materials and methods: Patients’ clinical symptoms, radiologic outcomes, hematologic, biochemical, D-dimer, and C-reactive protein
(CRP) results were obtained from their medical records. Participants were separated into 2 groups: one was treated with LMWH and
the other was not. Improvement in the patients was compared before and after treatment.
Results: Ninety-six patients who were diagnosed with COVID-19 between April and May 2020 were retrospectively analyzed. The
multivariable analysis showed that the count of lymphocytes, D-dimer, and CRP levels were significantly improved in the LMWH
group, as compared to the control group (OR, (95% CI) 0.628 (0.248–0.965), P < 0.001); OR, (95% CI) 0.356 (0.089–0.674), P < 0.001,
respectively). The area under the receiver operating characteristic (ROC) curve analysis was AUC: 0.679 ± 0.055, 0.615 ± 0.058, and
0.633 ± 0.057, respectively; the β-value was found to be –1.032, –0.026, and –0.465, respectively.
Conclusion: The LMWH treatment group demonstrated better laboratory findings, including recovery in the lymphocyte count, CRP,
and D-dimer results.
Key words: Coronavirus disease-19, heparin, antiinflammatory, lymphocyte

1. Introduction
The COVID-19 disease is an illness caused by a respiratory
and systemic zoonotic coronavirus. It was first recognized in
Wuhan, China, and it has continued to spread rapidly since
then. It has become a global calamity, and the World Health
Organization (WHO) declared the disease a pandemic on
March 11, 2020. Over 2 million people worldwide have been
infected so far, and mortality continues to rise. However, no
effective medical cure is available, and patients are treated
according to their symptoms and findings [1,2].
Helpful strategies for improvement of the illness
may be devised if the pathophysiology is understood.
Lymphopenia and cytokine storms are the typical
pathological changes detected in patients with coronavirus
infections; they relate to COVID-19 severity. The cytokine
storm is a key mechanism underlying disease exacerbation
and mortality in COVID-19 patients [3–5]. Some studies
have indicated that low molecular weight heparin
(LMWH) has some properties other than its anticoagulant

effects, such as its antiinflammatory action, which ensures
improvement in lymphopenia [6]. However, although the
antiinflammatory effects of LMWH in COVID-19 remain
unclear, it is thought that the antiinflammatory efficacy
contributes to the regression of COVID-19 [7]. The aim
of this study is to assess the clinical impact of LMWH
treatment on the clinical course of COVID-19.
2. Material and methods
In this study, 96 participants who were admitted to the
Selcuk University Hospital, Department of Pulmonology
between March and April 2020 were analyzed
retrospectively. The patients’ clinical outcomes were
investigated by studying their electronic medical records.
COVID-19 was diagnosed according to WHO guidelines.
This study was approved by the Ministry of Health
Committee (approval number: 2020/37) and conducted
in accordance with the principles of the Declaration of
Helsinki [2].
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Blood samples were gathered during the length of the
stay in the hospital: D-dimer, prothrombin time (PT),
international normalized ratio (INR), and fibrinogen (FIB)
measurements were investigated by utilizing a coagulation
analyzer device.
Participants were separated into 2 groups according to
D-dimer (D-dimer > 750 ng/mL) and PT (<12 s) outcomes
due to mortality, raised accordingly with D-dimer, PT
levels, and given appropriate thrombopropylaxis with
LMWH (a thromboprophylactic dose of 4000 UI/day for
7 days). No anticoagulant drugs other than heparin were
utilized for 7 days or longer in the research patients. All
the participants received appropriate treatment after
admission to the hospital [8–10].
2.1. Inclusion criteria
The inclusion criteria included: 1) satisfying the conditions
of the diagnostic standards of COVID-19 pneumonia
outlined by the Health Commission of Turkey, 2) identified
as tightness of breath, respiration rate (RR) ≥ 30/min,
detected typical lesions in CT images of viral pneumonia;
3) age ≥18 years; 4) no history of any pulmonary disease;
and 5) no immunosuppressive or corticosteroid agent
administered during the therapy period.
2.2. Exclusion criteria
The exclusion criteria included: 1) participants with severe
chronic diseases; 2) patients who had liver, kidney, or
cardiac disease; 3) patients who had taken LMWH therapy
in the last 3 months; 4) patients with a history of mental
disorders; 5) women who were pregnant or breastfeeding;
6) patients who had followed-up in the intensive care unit
(ICU); and 7) patients with any sensitivity to LMWH.
2.3. Chest CT severity score assessment
The computer tomography severity score (CT-SS) was
utilized to evaluate patients with COVID-19. The CT-SS
is an adapted version of the scoring system, describing
ground glass, interstitial opacity, and air trapping for
severe acute respiratory syndrome (SARS). This scoring
system assesses pulmonary lesions as a guide for detecting
the disease [11]. The lungs were separated into 20 zones,
according to human anatomy. The detected pulmonary
opacities in all zones were assessed by thin section
thorax CT (TST-CT), using system linked scores of 0, 1,
and 2, according to opacification, including 0%, < 50%,
or ≥ 50% of every zone. The total scores, which ranged
between 0 and 40 points, were obtained from each zone
collected. Two experienced thorax radiologists, who were
blinded to the identity of the participants, evaluated all
the CT screenings. Chest CT scans were performed with
a 256-detector CT scanner (Siemens, Germany). All the
participants were lying in the supine position, and the scan
was performed during the breath hold situation [11].

2.4. Data collection
The demographic characteristics (age, sex, and BMI),
signs and symptoms, clinical outcomes, initial knowledge,
complete blood count (CBC), D-dimer, FIB, coagulation
profile, inflammatory markers, biochemical markers (such
as liver function, CRP, and electrolytes), and the TSTCT of patients infected with COVID-19 were assessed
retrospectively (Tables 1–3). Two researchers assessed the
collected data forms independently.
2.5. Statistical analysis
The R 3.6.0 (www.r-project.com) was used to perform
all the statistical analyses. The Anderson–Darling test
and Q-Q plots were used to check the normality of the
variables. The homogeneity of the variances by group was
examined using the Levene’s test. Data was described as
mean ± standard deviation (range), median (interquartile
range), and numbers (%) for the general characteristics of
the patients with COVID-19. Welch’s t-test, the Mann–
Whitney U test, the χ2 test, with the Yates continuity
correction, and Fisher’s exact test were used, as appropriate,
to compare the general characteristics between the patient
groups. Considering the possible extreme outliers under
pandemic conditions, the values for the laboratory
findings were presented as trimmed mean (±SEM:
standard error of mean), which was calculated with a
10% trim proportion and a robust estimator against the
outliers. Yuen’s test (robust independent-samples t-test)
and the robust paired-samples t-test were used to compare
these findings. The comparisons were applied considering
4 situations: the LMWH and the control groups before
treatment, the LMWH and the control groups on the 7th
day of treatment, and the LMWH group before treatment
and on the 7th day of treatment (Figures 1 and 2). Finally,
calculated changes were compared by taking the difference
of the 7th day and before the treatment in both groups; P
< 0.001 was considered statistically significant. Univariate
logistic regression analysis was utilized to view risk factors.
A multivariate logistic regression analysis was performed
to evaluate the efficacy of the variant risk factors on the
participant’s discharge and scoring system; the odds ratio
(OR) and 95% confidence interval (CI) were calculated
(Tables 4,5). The forecasting value of the lymphocyte
count, D-dimer, and CRP, as assessed by the ROC curve
and the cut-off value, which may predict the discharge,
were identified afterward.
2.6. ROC curve analysis
The recovery performances of the laboratory parameters
were evaluated by ROC analysis on the 7th day, as shown
in Figure 3. The cut-off point for these parameters was
determined according to the Youden index value. Risk
factors included the lymphocyte counts, the level of CRP,
and the D-dimer. The contributions of the risk factors were
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Table 1. General characteristics of the patients infected with COVID-19.

LMWH Group
(n = 48)

Control Group
(n = 48)

P-value

53.3 ± 15.6

55.4 ± 11.6

0.469

Characteristics
Age (years)
Sex

0.667

Female

15 (31.3)

18 (37.5)

Male

33 (68.8)

30 (62.5)

Comorbidity

29 (60.4)

28 (58.3)

0.718

Hypertension

17 (35.4)

18 (37.5)

0.617

Diabetes mellitus

14 (29.2)

10 (20.8)

0.123

Coronary artery disease

7 (12.2)

5 (8.7)

0.831

Gastrointestinal disease

1 (2.1)

2 (4.2)

0.512

Other disease

6 (12.5)

3 (6.3)

0.486

Values were presented as mean ± standard deviation (min–max), median (min–max) or numbers
(n) and percentages (%).
P-values were calculated by Welch’s t-test, Mann–Whitney U test, χ2 test with Yates continuity
correction or Fisher’s exact test, as appropriate.

determined based on the β value presented in Table 5. The
area under the ROC curve for dividing the participants’
LMWH, as compared to the control group, was applied for
the threshold sensitivity, specificity, and accuracy. It was
OR; 0.356 (standard error, 0.001; 95% CI, 0.089–0.674, β;
–1.032) for lymphocyte, OR; 0.974 (standard error, 0.001;
95% CI, 0.476–1.594, β; –0.026) for D-dimer, and OR; 0.628
(standard error, 0.001; 95% CI, 0.248–0.965, β; –0.465) for
CRP. The optimal threshold for identifying patients was
1.39, with 66.7% sensitivity and 64.6% specificity; 414,
with 39.6% sensitivity and 85.4% specificity; and 14.3, with
58.3% sensitivity and 64.6% specificity, respectively.
3. Results
3.1. General characteristics of the patients with
COVID-19
The LMWH group consisted of 15 males and 33 females
aged between 40 and 68 years (average age: 53.3 years), as
shown in Table 1. The control group consisted of 18 males
and 30 females aged between 44 and 66 years (average age:
55.4 years). There was no substantial difference detected
between the groups.
There were no significant differences between the
groups in comorbidities such as diabetes mellitus,
hypertension, coronary artery disease, gastrointestinal
disease, cardiovascular disease, or other diseases. There
were also no significant differences in COVID-19
pneumonia onset symptoms, with the inclusion of fever
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(temperature ≥37.4 °C), dry cough, shortness of breath,
sputum, myalgia, throat ache, nausea or vomiting,
diarrhea, and headache. Similarly, there was no significant
difference in the conventional therapy between the groups.
These outcomes show that the general characteristics of
the patient groups were both congruous and comparable.
3.2. Effect of LMWH on the days to conversion to
negative and the length of the hospital stay of patients
with COVID-19
As shown in Table 2, the number of days it takes to convert
the virus to a negative outcome (time from the beginning
of the stay in the hospital until virus shedding) was 5.2
days (IQR 3.4–6.3) in the LMWH group and 7.6 days (IQR
6.5–9.7) in the control group (P < 0.001). A significant
difference was detected between the groups. Also, the
length of the stay in the hospital was 7.2 days (IQR 6.4–
8.3) in the heparin group and 9.6 days (IQR 8.5–10.7) in
the control group (P < 0.001). A significant difference
was detected between the groups. All of the participants
demonstrated improvement after the treatment.
3.3. Effect of LMWH on the blood routine in patients
with COVID-19
A significant difference was detected in the lymphocyte
count between the groups before and after treatment, as
shown in Table 2. The after-treatment lymphocyte count
of the LMWH treatment group participants was elevated,
and the detected difference was significant. In addition,
the changes in the lymphocyte counts in the LMWH
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Table 2. Signs, symptoms, and clinical outcomes.
LMWH Group
(n = 48)

Control
(n = 48)

P-value

Fever (temperature ≥37°C)

38 (79.1%)

36 (75.0%)

0.808

Dry cough

33 (68.8%)

30 (62.5%)

0.667

Shortness of breath

24 (50.0%)

28 (58.3%)

0.413

Sputum

13 (27.1%)

14 (29.2%)

0.825

10 (20.8%)

16 (33.3%)

0.251

Throat ache

8 (16.7%)

6 (12.5%)

0.772

Nausea or vomiting

1 (2.1%)

6 (12.5%)

0.135

Diarrhea

3 (6.9%)

4 (8.3%)

0.683

Headache

4 (8.3%)

2 (4.2%)

0.277

Time from initial symptoms to admission to hospital (days)

2.2(1.1–3.4)

2.4(1.6–3.2)

0.816

Time from hospitalization to viral shedding of disease (days)

5.2 (3.4–6.3)

7.6 (6.5–9.7)

<0.001

Signs

Myalgia

Length of stay in hospital

7.2 (6.4–8.3)

9.6 (8.5–10.7)

<0.001

Antibiotic therapy

48

48

0.997

Azitromycin

38 (79.1%)

39 (81.2%)

Moxifloxacin

42 (87.5%)

41 (85.4%)

Antiviral therapy

0.994

Favipiravir

32 (66.6%)

33 (68.7%)

Oseltamivir

43 (89.5%)

42 (87.5%)

Improved

48 (100%)

30 (62.5%)

Steady

0

18 (37.5%)

Disruptive

0

0

Score of left lung

5.0 (4.0–6.0)

6.0 (5.0–8.0)

<0.001

Score of right lung

5.0 (3.75–6.0)

7.5 (6.0–95)

<0.001

Total score

11.0 (7.0–12.5)

13.5 (12.5–16.0)

<0.001

Response to treatment
0.212

CT-SS

CT-SS: CT severity score

group before and after therapy were significantly different
according to the control group.
After treatment, the platelet results and levels were
significantly elevated in the LMWH group, compared
to the control group. However, there was no significant
difference detected between the groups in the monocyte,
neutrophil percent, white blood cell (WBC), or
hemoglobin levels.
3.4. Effect of LMWH on the coagulation function in
patients with COVID-19
The levels of the D-dimer and fibrin products prior to the
application of LMWH in both groups were nonsignificant;
however, these outcomes were significantly decreased after
the LMWH treatment in the LMWH group, compared to

the control group, as shown in Table 3. The patients’ levels
of D-dimer and FIB were significantly decreased in the
LMWH group prior to and after treatment. The outcomes
show that the application of LMWH improves the
hypercoagulable state in COVID-19 patients. However,
there was no significant difference detected in PT and
INR levels among the groups.
3.5. Effect of LMWH on the CRP in patients with
COVID-19
There were significant differences detected in the CRP
levels between the groups both prior to and after LMWH
treatment, as shown in Table 3. Although the CRP levels
were initially similar between the groups, these outcomes
were significantly decreased in the LMWH group.
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Table 3. Laboratory findings and scores during the treatment period.
Initial values

7th day of the treatment

LMWH
(n = 48)

Control
(n = 48)

pa

LMWH
(n = 48)

Control
(n = 48)

Pb

Pc

WBC (k/uL)

9.26 ± 0.76

9.51 ± 0.80

0.497

6.40 ± 0.41

6.91 ± 0.37

0.365

0.435

Neutrophil (k/uL)

5.43 ± 0.54

4.88 ± 0.43

0.402

4.95 ± 0.45

4.84 ± 0.32

0.828

0.408

Monocyte (k/uL)

0.55 ± 0.05

0.52 ± 0.04

0.609

0.58 ± 0.03

0.65 ± 0.05

0.260

0.523

Monocyte percent (%)

7.39 ± 0.49

7.93 ± 0.64

0.491

7.87 ± 0.53

8.99 ± 0.67

0.175

0.318

Lymphocyte (k/uL)1,39

0.77 ± 0.03

0.82 ± 0.02

0.094

1.39 ± 0.40

1.02 ± 0.03

<0.001

<0.001

Lymphocytes percent (%)

12.41 ± 1.06

13.66 ± 0.84

0.205

22.18 ± 2.02

19.86 ± 1.46

0.337

<0.001

HB (g/dL)

12.80 ± 0.35

13.29 ± 0.27

0.242

12.31 ± 0.31

12.96 ± 0.25

0.089

0.001

PLT (k/uL)

181.72 ± 11.83

189.05 ± 9.58

0.618

220.60 ± 11.17

229.15 ± 13.28

0.610

<0.001

ALT (U/L)

44.12 ± 5.26

43.63 ± 6.23

0.879

35.16 ± 3.64

36.17 ± 4.28

0.826

0.853

AST( U/L)

42.27 ± 3.45

43.72 ± 4.48

0.911

37.83 ± 4.95

35.82 ± 3.59

0.868

0.889

TB (mmol/L)

1.04 ± 0.13

1.06 ± 0.24

0.752

0.98 ± 0.26

1.00 ± 0.14

0.842

0.892

Na

138.25 ± 3.45

141.40 ± 2.48

0.764

142.26 ± 3.25

144.52 ± 4.28

0.815

0.795

K

4.32 ± 1.13

4.46 ± 1.48

0.827

4.53 ± 1.26

4.61 ± 2.01

0.874

0.855

Cre

1.10 ± 0.25

1.16 ± 0.44

0.745

0.98 ± 0.55

1.01 ± 0.62

0.825

0.794

CK-MB (ng/mL)

1.22 ± 0.15

1.28 ± 0.11

0.738

1.25 ± 0.15

1.33 ± 0.12

0.663

0.827

Troponin-I (ng/L)

9.46 ± 2.56

5.71 ± 0.79

0.152

9.06 ± 2.33

4.84 ± 0.99

0.089

0.750

PT (sn)

11.16 ± 0.15

13.36 ± 0.31

0.256

15.05 ± 0.13

11.78 ± 0.38

<0.001

<0.001

INR (INR)

1.03 ± 0.02

1.23 ± 0.03

0.540

1.43 ± 0.02

1.11 ± 0.04

0.069

0.229

D-DIMER (ng/mL) < 414

815.02 ± 112.24 650 ± 59.68

0.182

414.10 ± 45.73

635.63 ± 39.96

<0.001

<0.001

CRP (mg/L)

43.66 ± 9.93

0.134

14.32 ± 4.46

36.62 ± 3.09

<0.001

<0.001

FIB

588.24 ± 10.25

326.35 ± 12.25

550.37 ± 15.38

<0.001

<0.001

11.0 (7.0–12.5) 13.5 (12.5–16.0) <0.001

<0.001

CT-SS

41.76 ± 7.20

595.35 ± 12.36 0.627
15.3 (13.5–
15.0 (12.0–16.0)
0.983
16.5)

Values were presented as trimmed mean ± SEM (trimmed mean was calculated with 10% trim proportion); (SEM: standard error of
mean).
P-values were calculated with Yuen’s test (robust independent samples t-test) and robust paired samples t-test.
Pa shows the comparison between LMWH and control groups before the treatment.
Pb shows the comparison between LMWH and control groups on the 7th day of the treatment.
Pc shows the comparison between before and on the 7th day of treatment in the LMWH group.
Abbreviations: WBC: white blood cell; HB: hemoglobin; PLT: platelat; CK-MB: creatinine kinase–myocardial band isoenzyme; PT:
prothrombin time; INR: international normalized ratio; CRP: C-reactive protein; FIB: fibrinogen; ALT: alanineaminotransferase; AST:
aspartateaminotransferase; TB: total bilirubine, K: potassium; Na: sodium, Cre: creatinine.

3.6. Effect of LMWH on the cardiac markers in patients
with COVID-19
As shown in Table 3, there were no significant differences
detected in the creatine kinase isoenzymeB (CK-MB) levels
between the groups prior to and after LMWH treatment,
and the results of both groups were decreased, as compared
to prior to treatment. Similarly, there were no significant
differences detected in the troponin-I levels between the 2
groups.
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3.7. Effect of LMWH on the CT-SS in patients with
COVID-19
As shown in Table 3, there were significant differences
detected in the CT-SS between the groups prior to and
after LMWH treatment. Although the CT-SS was initially
similar between the groups, these outcomes decreased
significantly after LMWH treatment in the LMWH group,
as compared to the control group.
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Table 4. Univariate logistic regression analysis of risk factors with
COVID-19 improvement.
Univariable
OR (95% CI)

P value

Age

1.041 (1.018–1.057)

0.315

Sex

0.732 (0.457–1.104)

0.217

BMI (kg/m2)

0.538 (0.319–0.936)

0.472

CT-SS

12.30 (10.50–14.25)

<0.001

WBC (k/uL)

2.485 (1.821–3.178)

<0.001

Neutrophils (k/uL)

1.514 (1.137–1.749)

<0.001

Lymphocyte (k/uL)

0.203 (0.015–0.322)

<0.001

CRP (mg/L)

0.362 (01.131–0.926)

<0.001

D-DIMER (ng/mL)

0.657 (0.463–1.223)

<0.001

Fibrinogen

1.738 (1.176–2.549)

<0.001

Laboratory findings

Antiinflammatory markers

CT-SS: CT severity score, CRP: C reactive protein.

4. Discussion
Cytokine storms are related to corruption in infectious
illnesses, such as SARS and Middle East respiratory
syndrome coronavirus (MERS); they are also an important
cause of exacerbation in patients. Studies have revealed that
heparin has some specifications other than anticoagulant
properties. It performs antiinflammatory actions by
decreasing the extrication and biological efficacy of IL6. However, the antiinflammatory effects of heparin in
the COVID-19 disease are not fully known. The main
finding of this study is to evaluate the impact of LMWH
administration on the clinical course of the COVID-19
disease [12].
Although some studies have investigated the
nonanticoagulant efficacy of LMWH, the real impact
mechanism of LMWH remains unknown. This study
investigated the antiinflammatory effect of the LMWH
molecule and its contribution to improvement in the
COVID-19 disease. LMWH is a heterogeneous molecule,
and it has some features other than its anticoagulant
effects. One of the effects of LMWH application is that it
leads to a decline in inflammation. LMWH efficacy starts
with inhibition of leukocyte transmigration stages into
tissue. Heparin inhibits inflammation by its anticoagulant
efficacy; these properties are closely intertwined. Some
studies have investigated its antiinflammatory effect. In an
experimental model, Downing et al. found that LMWH
reduced inflammation and performed this efficacy without
any anticoagulant effects. Ahmed et al. also showed that

Table 5. Multivariate logistic regression analysis of risk factors
with COVID-19 improvement.
β

OR

(95% CI)

P

Lymphocyte (k/uL) –1.032

0.356 (0.089–0.674)

<0.001

CRP (mg/L)

–0.465

0.628 (0.248–0.965)

<0.001

D-DIMER (ng/mL)

–0.026 0.974 (0.476–1.594)

<0.001

inhaled heparin led to an improvement in pulmonary
functions and airway hypersensitivity in asthmatic patients
[13,14].
Although the initial results were similar in the assay
of distinctions of the lymphocyte counts, after the therapy
period, the lymphocyte counts were more elevated in the
LMWH group than the control group, which is consistent
with Huang et al. This shows that LMWH can elevate the
lymphocyte count and contribute to an improvement of
the disease. There are some causes for this. First, LMWH
consists mainly of oligosaccharides, and it can be explained
that short oligosaccharide chains, which are common in
LMWH, may lead to the compression of cytokine storms;
in addition, oligosaccharide chains, which are reproduced
from nitrous acid depolymerization of LMWH, are able to
bind to antithrombin-III (AT-III), and this indicates that
the therapeutic effect for the hypersensitivity of LMWH is
independent of the anticoagulant impact [15–21].
One large trial on sepsis demonstrated that LMWH
decreased mortality rates. This suggests that LMWH
regressed the inflammation by its nonanticoagulant effects.
Camprubi-Rimblas et al. revealed that LMWH may treat
acute respiratory distress syndrome (ARDS) by improving
lung inflammation. In addition, Paulsson et al. showed
that heparin might heal a lung infection by struggling
with heparan sulfate, which can cause a cytokine storm
in COVID-19 by preventing the pathogens that bind host
cells. However, the RASTEN study revealed that there was
no significance detected in the survival time in lung cancer
patients; although this was a disappointing outcome
for LMWH, the dose of the molecule in this study was
prophylactic, and the stage of the participants was higher;
therefore, these results are incongruous [22–24].
Researchers and medical personnel have found that
age and comorbidity are possible risk factors for patients
who are infected with COVID-19. Moreover, some studies
have demonstrated that thorax CT scans and laboratory
markers, such as complete blood count, liver enzyme
markers, coagulation parameters, inflammatory markers,
and the quantity of immune cells of COVID-19 patients,
are connected with the severity of the illness [25–27].
In some studies on COVID-19, the D-dimer levels
were increased substantially according to disease severity.
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Figure 1. Effect of LMWH on lymphocyte (k/uL) in the patients with COVID-19.
Data were expressed as mean ± SEM. (A): Comparison between LMWH and control
groups before the treatment; (B): Comparison between LMWH and control groups
on the 7th day of the treatment. (C): Comparison between before and on the 7th day
of the treatment in the LMWH group. (D): Comparison between the changes, which
were calculated by taking the difference between the 7th day results and the results
collected before the treatment in both groups.

Figure 2. Effect of LMWH on D-Dimer (ng/mL) in the patients with COVID-19.
Data were expressed as mean ± SEM. (A): Comparison between LMWH and control
groups before the treatment. (B): Comparison between the LMWH and control
groups on the 7th day of treatment. (C): Comparison between before and on the 7th
day of the treatment in the LMWH group. (D): Comparison between the changes,
which were calculated by taking the difference between the 7th day results and results
collected before treatment in both groups.

Tang et al. found that elevation of the D-dimer outcomes
was correlated with mortality. Furthermore, Zhang et al.
detected that elevated results of D-dimer affects hospital
mortality, so this is a helpful parameter for following
up the improvement of COVID-19 patients. Therefore,
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D-dimer was used as an evaluation index marker for
the progression of the illness in this research. The mean
outcomes of D-dimer were higher in the LMWH group
than in the control group. This outcome is in line with
the achievement of the LMWH performed group. The
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Figure 3. ROC curve for risk factors in patients infected with COVID-19. ROC = receiver
operating characteristic.

determination of the differences demonstrated that
LMWH had better efficacy for lowering D-dimer levels
[11,28].
Novel studies have suggested that analyzing the CRP
and lymphocyte counts revealed the efficacy of treatment
of COVID-19. When we touched on the differences
between the groups, significant differences were detected
in the decreasing of the CRP results and the elevation in
the lymphocyte counts of the LMWH group, as compared
to the control group [29,30].
In the study analysis of CRP outcomes, Walters et al.
indicated that LMWH reduces CRP outcomes, indicating
its antiinflammatory effect. Furthermore, the ARMADA
study revealed that inflammatory markers such as CRP
were decreased in the heparin group. According to the
control group, the CRP outcomes in the present study
were lower in the LMWH group after the therapy period,
which is in line with Walters et al. and the ARMADA
study. This showed that LMWH can improve CRP levels
and contribute to improvement of the disease [31,32].
Novel studies have also investigated some
pathobiological perspectives, such as acquired
thrombophilia in COVID-19, which were not evaluated

previously and may enlighten future research. Patients with
COVID-19 frequently have a higher risk for thrombotic
situations. Therewithal, fibrin-based occlusions in
microvessels have been found in the lung histopathology
specimens examined in deceased COVID-19 patients
[33–35].
Some synergistic mechanisms such as hypoxic
vasoocclusion, activation of cells by viral transduction, and
cytokine storms, which have been detected in COVID-19,
may lead to micro- and/or macrothrombosis [36,37].
Furthermore, numerous studies have demonstrated that
activated neutrophils conduce the spreading of thrombus,
which affects vascular beds [38,39].
In accordance with these pathophysiological outcomes,
some conventional gargling drugs suggested in the initial
treatment of COVID-19 for leading oropharyngeal viral
shedding, such as Ankaferd hemostat, contain Glycyrrhiza
glabra, which contributes to antiinflammatory efficacy by
way of a decline in the high mobility group box 1 protein
[HMGB1] secretion [40].
Through the logistic univariate regression model, this
study detected that WBC outcomes, the lymphocytes
count, neutrophils, D-dimer, FIB, CRP, and PLT were
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independent risk factors for participants. Moreover, some
studies have shown that most of the patients infected with
COVID-19 displayed lymphocytopenia, elevated D-dimer
levels, CRP, and, in some cases, elevated liver enzymes
such as AST and ALT. Hematologic and biochemical
outcomes were seriously elevated in patients who were
followed up at an ICU, recommending that the severity
of the disease may have a relationship with cytokine
storms and hyper inflammation. In addition, the logistic
multivariate analysis model demonstrated that D-dimer,
CRP levels, and lymphocyte counts were the main risk
factors for disease severity, which has a relationship with
inflammation and hypercoagulation [41,42].
Although some scoring modules have more variables
correlated with disease prognosis, no scoring system has
been accepted as a rule. Gong et al. formulated a sevenparameter system that included complete blood count
and biochemical markers for identification of severity
[43]. Chen et al. also performed a system for predicting
the prognosis of the disease, including comorbidities,
antiinflammatory markers, and demographics [44]. The
present study utilized the scoring system designed by
Dong et al. for evaluating disease severity and assessing
the treatment time by a simple formula, in comparison
to other systems that are confusing and may lead to
misunderstandings [45]. Although the present system
only contains 3 variables, it has better efficacy for
distinguishing participants whose progress may turn to
severity and respond to treatment conveniently. CRP was
used as a scoring parameter, instead of the erythrocyte
sedimentation rate (ESR), for evaluating antiinflammatory
efficacy more clearly [46]. In comparison to these studies,
the present scoring system is a simple and rapid detecting
module for patients whose prognosis may become worse.
In addition to the scoring system, this research assessed
the TST-CT outcomes for evaluating the improvement of
patients and used it to assist in observing the improvement
in the lungs. TST-CT is a sensitive apparatus and is
better than chest x-rays for investigating the pulmonary
parenchyma. Therefore, this method has become a pioneer
diagnostic, and it is a helpful method for early detection
of COVID-19. The characteristic radiological outcome of
COVID-19 is ground-glass opacities and/or consolidation
asymmetrically located at peripheral lodges. The
radiological manifestations are similar to those of SARS
and MERS. The SARS and MERS diseases both frequently

show single lesions unilaterally and asymmetrically in the
lungs. The TST-CT scores and the screened lesions were
improved at the end of the follow-up period, according to
the initial time outcomes [47,48].
This study had some limitations. First, it was a
retrospective study, and the patient population was small;
however, the sample size was considered adequate to
draw relevant conclusions. The present study showed that
research groups have an inclusive population treated in our
center. Second, none of the patients who were treated in the
ICU joined the study; all the participants were discharged
and had no complications or mortality detected. Finally,
the influence of other novel therapies on these patients was
not evaluated. Because the research period lasted a little
over 1 week, it is possible that some nonpharmacological
changes were introduced in the management of patients
as medical institutes learned more about this disease over
time.
5. Conclusion
In conclusion, this research suggests that LMWH therapy,
added to conventional treatment, can contribute to
clinical and laboratory improvement in COVID-19. Those
improvements might be the result of the antiinflammatory
effects of LMWH.
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